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ABSTRACT 
 
Pattern classification is a branch of statistics and machine learning that 
uses labeled samples to predict information about unlabeled ones. A common 
application of this theory in medicine is to classify cancer patients into subtypes 
based on the patterns of their gene expression profiles. What determines the 
validity of the procedure is not whether one can find these patterns in observed 
data, but whether these patterns generalize to unobserved data from the same 
population. In this regard, the error of the classification rule over the population 
determines its validity and a key issue is how to estimate it.  
In small sample situations, where the number of observed data is small, 
estimating the classification error becomes problematic as most of the error 
estimators have high variance. This raises doubts on the replicability of small-
sample studies. In this thesis, I will use a replicability index to asses multiple 
classification and error estimation procedures that are commonly used in the 
medical community, and in particular, on RNA-seq and microarray gene 
expression data, and provide suggestions on the sample size to ensure that a 
procedure applied to a small preliminary study will generalize in a large follow-on 
study with an acceptable margin of error.   
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INTRODUCTION 
 
Many recent cancer diagnosis and prognosis studies have suggested that 
gene expression profiles, such as microarrays and RNA-seq data, may serve as 
reliable detectors/predictors of several cancers or their outcomes. While trying to 
discover these clinically useful biomarkers, a preliminary study with a small set of 
specimens is conducted, then a statistical analysis or machine learning 
procedure is carried out and if the results are satisfactory, a follow-on study with 
a large set of samples is conducted to validate the findings.  
Notwithstanding the expectation, it has been estimated that as much as 
75% of published results are not replicable [14], which implies that most of the 
reported biomarkers perform poorly on data other than the one they were 
designed on. There has been an increasing discussion about the reproducibility 
crisis [2,5,9] and the quality and generalizability of biomedical research [4].  
Reproducibility issues are associated to the measurement platform, 
specimen handling, sample compatibility between studies and their normalization 
[5]. Replicability is concerned with the statistical analysis and inference methods 
chosen to either make decisions or support/rule out potential hypotheses. The 
former can be alleviated through the standardization of sample processing and 
data sharing protocols. Mitigation of the latter, however, requires a careful 
analysis of statistical significance and error. In the context of cancer diagnosis 
and prognosis, classifier error estimation and its accuracy is key to replicability of 
a medical test. 
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In my research, I analyze the replicability of classification procedures used 
on microarray and RNA-seq data. Microarray is a relatively old technology that 
measures the expression levels of multiple genes simultaneously, using image 
processing techniques, while RNA-seq is a technology that uses next-generation 
sequencing (NGS) to measure the abundance of RNA transcripts, and thus gene 
expression, in a biological sample. Given a collection of gene expression profiles 
from two or more different biological conditions, such as healthy individuals and 
cancer patients, statistical and machine learning methods can be used to classify 
a sample into one of the conditions. Replicability of an interesting preliminary 
medical classifier involves assessing its validity based on a large independent 
follow-on study.  
It is often expected that not only the follow-on study will confirm findings of 
the preliminary study, but also provides a more accurate error estimate. 
However, it has been reported that most of the medical studies are not replicable, 
meaning that the reported error rate is significantly off [2,6, 17]. The statistical 
and machine learning communities have long known that the sample size affects 
the classification error rate, and more importantly the accuracy of its estimator. 
Collecting biological samples is expensive. This constrains the size of a typical 
preliminary study to be small, which jeopardizes the validity of the entire 
classification and error estimation procedure. It is thus crucial to provide a formal 
framework to address generalizability of a classification procedure, without 
wasting valuable resources on testing classifiers that are simply not good. 
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We use a probabilistic quantity, termed as the replicability index, to 
characterize how often a follow-on gene expression classification study yields 
results that are at least as good as those in the preliminary study. More 
importantly, if a researcher desires a certain level of replicability for a preliminary 
study, this quantity can be used to suggest the minimum sample size necessary 
to guarantee that level. We test this index on a multitude of classification 
procedures and data generation models that mimic real-world gene expression 
studies. 
  
METHODOLOGY 
 
(Gene Expression Data Models) 
Two models are used to generate synthetic expression data. Both the 
models are built using parameterized multivariate distributions, each representing 
a biological condition. Sample points are generated from two classes with 𝑝 
features. Thus, each sample point is specified using a feature vector 𝑿 ∈ 𝑅𝑝 and 
a label 𝐾 ∈ {0,1}. Let 𝑛 denote the number of patients (or, samples) in the 
preliminary small sample study. So, a study of 20 patients with 10,000 genes 
each means that number of samples are 20 and number of features are 10,000. 
number of features are 10,000. 
 
Microarray Model 
For microarray simulation, we are using the model developed by Hua et 
al., 2005 [8]. The class-conditional densities are multivariate Gaussian with 
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𝑓(𝑥|𝐾 = 𝑘) ~ 𝑁𝑝(𝜇𝑘, 𝛴𝑘) for 𝑘 ∈ {0,1}  where 𝜇0 and Σ0 are 𝑝×1 mean vector and 
𝑝×𝑝 covariance matrix of class 0, and 𝜇1 and Σ1 are the mean vector and 
covariance matrix of class 1. To set the values of these parameters, we break 
them into smaller groups of parameters that signify biological properties of 
microarray samples in cancer studies.  
We assume features belong to one of the two groups of markers and non-
markers. Markers are the genes associated with a disease or condition related to 
the disease and they have different class-conditional distributions for the two 
classes. They are further categorized into two subgroups: global markers and 
heterogeneous markers [7]. Global markers take values from 𝐷𝑔𝑚- dimensional 
Gaussian distribution with parameters (μ0
gm
, Σ0
gm
) for sample points from class 0 
and (μ1
gm
, Σ1
gm
) for sample points from class 1. Heterogeneous markers, on the 
other hand, are divided into two subgroups of equal size, each associated with 
one of two mutually exclusive subclasses within class 1. Therefore, a sample 
belonging to 1 of the subclass takes values from 𝐷ℎ𝑚- dimensional Gaussian 
distribution with parameters(μ1
hm, Σ1
hm). The same markers for sample points 
belonging to the other subclass and class 0 take values from a Gaussian 
distribution with parameters (μ0
hm, Σ0
hm). 
We assume identical covariance structures for both global and 
heterogeneous markers, meaning that Σ0
gm
= Σ1
gm
= Σ0
hm = Σ0
hm = 0.62 Σ. We 
assume that Σ has a block matrix structure with zeros off the diagonal, and 
identical 5×5 matrices, Σρ, on the diagonal. Further, Σρ itself has 1 on the 
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diagonal and 0.4 for the rest. As for the mean vectors, we assume global 
markers and the heterogeneous markers have the same mean vectors: 
{𝜇0
𝑔𝑚
, 𝜇1
𝑔𝑚} = {𝜇0
𝑔𝑚
, 𝜇1
𝑔𝑚} = {𝜇0, 𝜇1}. Furthermore, we set 𝜇0 = [0,0, … , 0]
𝑇 and 
𝜇1 = [𝜃, 𝜃, … , 𝜃]
𝑇. Here 𝜃 may be fixed or may be random, in which case it has a 
probability distribution.  
Non-markers are also divided into two subgroups: high-variance non-
markers and low-variance non-markers [7]. High-variance non-markers are 
uncorrelated and they follow the distribution given by a Gaussian mixture 
distribution 𝜈 𝑁(0,0.62) + (1 − 𝜈)𝑁(𝜃, 0.62), where 𝜈 ~ 𝑈𝑛𝑖𝑓(0,1). Low-variance 
non-markers are also uncorrelated with identical one dimensional Gaussian 
distribution with 𝑁(0,0.62). Figure 1 represents the block-based structure of the 
model. Simulation parameters for this data model are also listed in Table 1.  
 
Parameters Value 
Feature Size 20,000 
Training sample size (equal size classes) 40 to 200 
Testing sample size 5000 
Mean of class 1 (𝜃) Fixed: 1. 167 
Random: 𝑁(1.167,0.036) 
# Global Markers  20 
# Subclasses 2 
# Heterogeneous Markers per Subclass 50 
# High-variance non-markers 2000 
# Low-variance non-markers 17880 
Table 1: Parameters for microarray simulations 
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Figure 1: Block matrix structure for microarray data 
 
RNA-seq Model 
In this work, we use RNA-seq model developed by Witten, et al., 2012 
[16]. We denote RNA-seq data in the form of an 𝑛×𝑝 matrix, 𝑿, with each 
element representing the number of reads in a gene. 𝑿 represents 𝑛 
observations with 𝑝 features. This data is usually assumed to follow a Poisson 
log linear [12] or Negative Binomial distributed model [1].  
Just like microarray, here we assume that observations are drawn from 
population containing two biological conditions. The model can be written as:  
𝑓(𝑥|𝐾 = 𝑘) ~ 𝑁𝐵(𝑁𝑖𝑗, 𝜙𝑗) , 
where 𝑁𝑖𝑗 = 𝑠𝑖𝑔𝑗𝑑𝑘𝑗 [16] is the mean of the distribution and 𝜙𝑗 is the dispersion 
parameter. This factor 𝑠𝑖, (also called size factor/sequencing depth) will be used 
to reflect that different samples may be sequenced to different depths. [12,13] 
The factor 𝑔𝑗  reflects the variability in the total number of reads per sample. 𝑑𝑘𝑗 
(also called differentially expressed parameter) is used to reflect if features are 
differentially expressed (DE) [3,12]. The probability of a feature being DE is 0.01 
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or 0.05, depending on the simulation. If a feature is differentially expressed, then 
log(𝑑𝑘𝑗) is Gaussian with a given mean and variance. Also, for features that are 
DE, we introduce a parameter 𝜃 to control the mean of their distribution.  
Parameters Value 
Feature Size 10,000 
Training sample size (equal size classes) 40 to 200 
Testing sample size 5000 
𝑠𝑖 𝑈𝑛𝑖𝑓(0.2, 2.2) 
𝑔𝑗 𝐸𝑥𝑝(1/25) 
𝑑𝑘𝑗 for all k if not differentially expressed 1 
Mean of log(𝑑𝑘𝑗) if differentially expressed (𝜃) Fixed: 0 
Random: 𝑁(0,0.036) 
Variance of log(𝑑𝑘𝑗)  if differentially expressed  0.0025 
Dispersion Parameter (𝜙) 0.1 
Table 2: Parameters for RNA-seq simulations 
In real situations, sequencing data tends to be over-dispersed compared 
to a Negative Binomial model. This can be accounted for by transforming the 
data using a power transformation with parameter 𝛼 ∈ (0,1] [11,16]. To this end, 
the transformation 𝑋𝑖𝑗
′ ← 𝑋𝑖𝑗
𝛼  is done, where 𝛼 is chosen such that: 
∑ ∑
(𝑋𝑖𝑗
′ − 𝑋𝑖∙
′  𝑋∙𝑗
′ 𝑋∙∙
′⁄ )
2
𝑋𝑖∙
′  𝑋∙𝑗
′ 𝑋∙∙′⁄
 𝑝𝑗=1
𝑛
𝑖=1 ≈ (𝑛 − 1)(𝑝 − 1), 
 where 𝑋𝑖∙
′  =  ∑ 𝑋𝑖𝑗
𝑝
𝑗=1  , 𝑋∙𝑗
′  =  ∑ 𝑋𝑖𝑗
𝑛
𝑖=1   and 𝑋∙∙
′ = ∑ 𝑋𝑖𝑗𝑖,𝑗 . 
 
(Classification Techniques) 
Classifier rule model is defined as a pair (Ψ, Ξ), [17] where Ψ is a 
classification rule, and Ξ is an error estimation rule on training data of the feature-
label distribution 𝐹.  In a typical classification task, a random training set 𝑆𝑛 =
{(𝑋1, 𝐾1), (𝑋2, 𝐾2), .  .  . , (𝑋𝑛, 𝐾𝑛)} [7] is drawn from 𝐹 and then a classifier 𝜓𝑛 =
 Ψ(𝑆𝑛) is designed which takes 𝑿 as input and outputs a label 𝐾. The true 
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classification error is given as 𝜀𝑛 = 𝑃(𝜓𝑛(𝑿) ≠ 𝐾). [7]. Then an error estimation 
rule Ξ is used to estimate the error as  𝜀?̂? = 𝛯(𝑆𝑛) for a classifier 𝜓𝑛. 
 
1. Linear Discriminant Analysis (LDA) 
LDA is a plug-in rule for Bayes classifier when class densities are Gaussian 
with a common covariance matrix. LDA assigns the label 1 to sample point 𝑿, if 
and only if  
(𝑿 − 𝜇1)
𝑇
Σ̂−1(𝑿 − 𝜇1) ≤  (𝑿 − 𝜇0)
𝑇
Σ̂−1(𝑿 − 𝜇0), 
where 𝜇𝑘is the sample mean for classes 𝑘 ∈ {0,1}, and Σ̂ is the sample 
covariance matrix. Since LDA is a classifier that is designed on a Gaussian 
distributed data, we expect it to perform well on microarray gene expression 
data.  
 
2. Sparse-Poisson Linear Discriminant Analysis (Sparse-PLDA) 
If we assume that the data is coming from a Poisson or a Negative Binomial 
distribution, we expect a model based on a similar distribution to perform better. 
This is a common assumption made for RNA-seq data [11,15,16]. We apply s-
PLDA exclusively to RNA-Seq data. We estimate the parameter given in the 
method in the following manner: We estimate 𝑔𝑗 as  ?̂?𝑗 = 𝑿∙𝑗. The size factors 
𝑠1, 𝑠2, .  .  . 𝑠𝑛 are estimated using Maximum Likelihood Estimator (MLE) for 𝑁𝑖𝑗  as 
?̂?𝑖 = 𝑿𝑖∙/𝑿∙∙ . We also use a shrinkage estimator for ?̂?𝑘𝑗 as: 
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?̂?𝑘𝑗 = 
{
 
 
 
 
𝑎
𝑏
−
𝜌
𝑏
      𝑖𝑓 √𝑏 (
𝑎
𝑏
− 1) < 𝜌
𝑎
𝑏
+
𝜌
𝑏
      𝑖𝑓 √𝑏 (1 −
𝑎
𝑏
) > 𝜌
1              𝑖𝑓 √𝑏 |1 −
𝑎
𝑏
|  < 𝜌
 
where 𝐶𝑘 ∈ {0,1}, 𝑎 =  𝑋𝐶𝑘 + 𝛽 , 𝑏 =  ∑ ?̂?𝑖𝑗 + 𝛽𝑖∈𝐶𝑘 , 𝑋𝐶𝑘 = ∑ 𝑿𝑖𝑗𝑖∈𝐶𝑘  and ?̂?𝑖𝑗 = ?̂?𝑖?̂?𝑗. 
Here 𝜌 is a non-negative tuning parameter that is found using cross validation. In 
the simulations, we assume 𝛽 = 1.  
Let 𝑦∗ be the unknown label of testing sample. The classifier finds the 
probability of the testing sample 𝑋𝑗
∗ having a label 𝑘 by [16]: 
log P(𝑦∗ = 𝑘|𝑋𝑗
∗) = ∑ 𝑋𝑗
∗ log ?̂?𝑘𝑗
𝑝
𝑗=1 − ?̂?
∗∑ ?̂?𝑗 ?̂?𝑘𝑗
𝑝
𝑗=1 , 
where ?̂?∗is the sequencing depth estimate of the testing sample. We assign the 
label 𝑘 to the 𝑦∗ value with higher probability. Here, to simplify the analysis, we 
assume that both the classes have equal prior probability. 
 
3. k-Nearest Neighbor 
k-NN classifies a new sample using k nearest training data samples nearest 
to the testing sample. Both the nearest ‘distance’ and the number of samples k 
can be adjusted while classifying the data.  
 
4. Support Vector Machines 
SVM finds a maximal margin hyperplane for a given set of training sample 
points [7]. If data cannot be separated by a linear function, some slack variables 
can be introduced in the optimization process to solve the problem. Otherwise, 
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one can transform the data by projecting it into a higher-dimensional space, 
where it is linearly separable.  
 
 
(Error Estimators) 
1. 𝒌 Fold - Cross Validation 
In 𝑘F-CV, the training sample, 𝑆𝑛 is randomly partitioned into 𝑘 folds 𝑆𝑛
𝑖  for 𝑖 =
1,2, … 𝑘 [7]. Now, each fold is held out the classifier design and then used as a 
test set. A classifier 𝜓𝑛
𝑖  is designed on the remaining sets 𝑆𝑛\𝑆𝑛
𝑖  and the error of 
the classifier is estimated by counting the misclassified sample points. The error 
is estimated by averaging the error for each fold. To reduce the variance due to 
random selection of the partitions, we repeat this process 10 times and then take 
the mean of the error as the 𝑘F-CV estimated error. We take 𝑘 = 5 for our 
simulations.  
 
2. Resubstitution  
In resubstitution error estimator we train and test the classifier on the same 
training data to find the error in classification. This estimation technique is very 
heavily biased on the training samples and thus we expect poorest estimates 
using this method. 
 
3. 0.632 Bootstrap 
In bootstrap error estimator, a bootstrap sample is made by drawing 𝑛 equally 
likely points with replacement from the original data. Then a classifier is designed 
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on the bootstrap sample and its error is calculated by finding the number of 
misclassified samples. Then a bootstrap zero estimate is found by finding the 
expected value of this error with respect to the bootstrap sampling distribution. 
We find this using 100 independent bootstrap samples. In 0.632 bootstrap 
estimator, we also add the estimate from resubstitution to incorporate for biasing 
of bootstrap towards training samples. Thus, 
0.632 𝜀?̂?𝑜𝑜𝑡 = (0.368 ∗ 𝜀?̂?𝑒𝑠𝑢𝑏) + (0.632 ∗ 𝜀?̂?𝑒𝑟𝑜). 
 
(Replicability Index) 
We use a probabilistic measure for whether a classifier that shows 
promising results in a small sample study will perform well on a larger 
independent sample [17]. We say that the original study will replicate with 
accuracy 𝜌 ≥ 0 if  𝜀𝑛 ≤ 𝜀?̂? + 𝜌. 
Any error estimate will not lead to a follow-on study, since the estimated 
error should be sufficiently small to motivate further analysis of the classification 
procedure. We will use 𝜏 as a threshold value of error, such that the follow-up 
study occurs if and only if  𝜀?̂? ≤ 𝜏. We define replicability index as: 
𝑅𝑛(𝜌, 𝜏) = 𝑃(𝜀𝑛 ≤ 𝜀?̂? + 𝜌|𝜀?̂? ≤ 𝜏). 
The pipeline to estimate the replicability index is as follows: 
1. Generate the training and testing data. 
2. Design classification method on the small size training samples. 
3. Find the true error and estimated error of the designed classifier. 
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4. Find the replicability index based on required values of threshold and 
accuracy parameters.  
The pipeline is also shown in Figure 2. 
 
 
Figure 2: Pipeline to find the replicability index 
 
RESULTS AND DISCUSSION 
Based on the steps mentioned in the previous section, we determined the 
replicability index of multiple classifier – error estimator combinations. We use 
LDA, SVM and 5-NN on simulated microarray data and s-PLDA on the simulated 
RNA-seq data. We apply cross validation, 0.632-bootstrap and resubstitution to 
find the estimated error of the combination.  
 
(Microarray Simulations) 
Figure 3 shows the expected replicability index, when 𝜃 is random, with 
respect to different sample size 𝑛, 𝜌 and 𝜏. We observe that there is a direct 
• Generate training and testing data using the 
appropriate distribution
• Design Classifier on the training sample.
• Find the true error and estimated error using 
error estimation method.
• Calculate the replicability index of the 
classifier and estimator combination.
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correlation between expected replicability index and the training sample size. But 
we also observe that after a certain sample size, we don’t see much 
improvement in the value of replicability index. Therefore, this gives a researcher 
an estimate of number of sample that the study requires to get a desired 
expected replicability of their method. For example, if required replicability is 0.8 
and 𝜏 = 0.1 , 𝜌 = 0.03, the sample size should be about 120. 
Figure 4 shows the effect of 𝜏 and 𝜌 on the replicability of the classification 
procedure for 𝑛 = 40 when 𝜃 is fixed. We see that as we increase the value of 
threshold parameter 𝜏, the estimated replicability index increases, which is 
expected. These plots give us an idea about the performance of our method and 
what threshold error values should we expect from it. This also gives a nice 
comparison amongst different classification and error estimation techniques and 
thus might help a researcher understand the replicability degree of their 
classification procedure. 
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Figure 3: Replicability for LDA classification rule and 0.632 bootstrap and 5F-CV for 
microarray data (𝑑 = 5 features are selected using t-test): 𝜏 = 0.05, 0.1, 0.15, 𝜌 =
0.01, 0.03 
 
Figure 5 has similar type of plots as Figure 4, but with 𝑛 = 120 samples. 
We observe very similar trends in Figure 5 and Figure 4. The differentiating factor 
between the plots are the value of threshold parameter 𝜏 corresponding to a 
replicability value. In general, for 𝑛 = 120, we observe that we get higher values 
of replicability for same value of 𝜏 than for 𝑛 = 40, regardless of the analysis 
method. These results support the correlation between sample size and 
replicability index, we saw from Figure 3. 
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(RNA-Seq Simulations) 
 
Figure 6 and 7 show replicability index plots for RNA-seq data. Figure 6 
shows similar plots to Figure 3, when 𝜃 is random. We plot replicability index with 
respect to different sample size 𝑛, 𝜌 and 𝜏. Like Figure 3, replicability of 
classification procedure shows direct correlation to training sample size. But we 
observe that replicability in general is quite low, even for higher training sample 
size. Thus, we expect that even higher training size would give us better 
replicability values. 
Figure 7 supports the observations from Figure 6. When we plot 
replicability index for various values of 𝜏 and 𝜌, for a fixed 𝜃, we see that for low 𝜏 
values, replicability is near 0, meaning that our classifier error rates are pretty 
high in comparison to those from microarray. Also, we see that the higher 
probabily of DE features in the classifier, the better the classifier performance is. 
This is expected and can be attributed to more features being used in classifier 
training. 
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Figure 4: Replicability index for microarray using 𝑛 = 40 using LDA, SVM, 5NN 
classification rule, 0.632 bootstrap, 5F-CV estimator rule for multiple values of 
𝜏 and 𝜌. 𝑑 = 5 features are selected using t-test 
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Figure 5: Replicability index for microarray using 𝑛 = 120 using LDA, SVM, 5NN 
classification rule, 0.632 bootstrap, 5F-CV estimator rule for multiple values of 
𝜏 and 𝜌. 𝑑 = 5 features are selected using t-test 
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Figure 6: Replicability for RNA-seq: s-PLDA classification rule and 0.632 bootstrap and 
5F-CV with 𝜏 = 0.3, 0.4, 0.5, 𝜌 = 0.075, 0.1, 0.15  
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Figure 7: Replicability index for RNA-seq using 𝑛 = 40, 120 using s-PLDA classification 
rule, 0.632 bootstrap, 5F-CV estimator rule for multiple values of 𝜏 and 𝜌. 
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CONCLUSION 
Performance replicability is an epistemological issue for any classification 
study. Replicability addresses the issue of accuracy of an error estimate. Larger 
the difference between estimated and true error, further we are from knowledge 
about the conclusion from preliminary study. If there is no measure of 
replicability, we have no justification to support a follow-up study. Thus, the issue 
of replicability should be settled prior to any large sample study. 
In this project, we studied about the issue in replicability of classification in 
gene expression data. The issue of replicability is an important topic to discuss in 
this case because the problem of small sample is one that cannot be overcome, 
due to simply the cost of such experiments and the time required to collect 
medical samples. For this kind of study, we assume some prior knowledge about 
the data. It may be argued that prior assumption may be erroneous and end 
results might have a different conclusion. But if sufficient knowledge is not 
accepted for an experiment, we are not ready to do the experiment.  
If we assume some knowledge about the data and find replicability of our 
method, we might save much more resources by not being over optimistic about 
our method. This study provided information to a researcher conducting a small 
sample study about number of sample points required in a preliminary study to 
get an accurate estimate of replicability of the method. This would help get a 
better understanding and avoid potential over-optimism in accessing a research 
methods’ reliability. 
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